Cannabics Pharmaceuticals Inc (OP: CNBX )

0.1800 USD +0.0020 (+1.12%)

Streaming Delayed Price Updated: 10:27 AM EDT, Apr 23, 2021 Add to My Watchlist

Price and Volume

Volume	52,879
Open	0.1800
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.1780
Today's Range	0.1675 - 0.1800
52wk Range	0.1350 - 0.6000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program

April 20, 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin...

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

March 31, 2021

Performance

YTD	-21.74%	-21.74%
1 Month	-43.91%	-43.91%
3 Month	-42.86%	-42.86%
6 Month	-0.72%	-0.72%
1 Year	-28.00%	-28.00%

More News

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

March 17, 2021

Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

February 17, 2021

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

February 16, 2021

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

February 03, 2021

Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

December 21, 2020

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

November 16, 2020

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

November 09, 2020

Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application

October 27, 2020

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

October 21, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.